Authors' recommendations: Description of Technology: Cariprazine (Vraylar) is an orally administered atypical antipsychotic agent used to treat patients with acute exacerbation of schizophrenia or acute manic or mixed episodes associated with bipolar I disorder. Among antipsychotic drugs, the binding affinity profile of cariprazine is most similar to that of aripiprazole. Cariprazine acts as a partial agonist, having high affinity for the dopamine D3 and D2 receptors and moderate affinity for serotonin 5-HT1A receptors. Its moderate to low binding affinity for histamine H1 and 5-HT2C receptors may be associated with fewer endocrine and metabolic side effects and less sedation. Its 6- to 10-times higher affinity for the D3 receptor than the D2 receptor might improve cognitive deficits and mood and reduce side effects. Lower binding affinity at the 5-HT1A receptor may be responsible for improvement in the negative symptoms of schizophrenia. Patient Population: Cariprazine is used to treat patients with acute exacerbation of schizophrenia or acute manic or mixed episodes associated with bipolar I disorder.

Project Status: Completed

Year Published: 2016

URL for published report: The report may be purchased from: http://www.hayesinc.com/hayes/crd/?crd=38066

English language abstract: An English language summary is available

Publication Type: Not Assigned

Country: United States

Organisation Name: HAYES, Inc.

Contact Address: 157 S. Broad Street, Suite 200, Lansdale, PA 19446, USA. Tel: 215 855 0615; Fax: 215 855 5218

Contact Name: saleinfo@hayesinc.com

Contact Email: saleinfo@hayesinc.com

Copyright: 2014 Winifred S. Hayes, Inc